13-Cis-retinoic acid: Pharmacology, toxicology, and clinical applications for the prevention and treatment of human cancer

Frank L. Meyskens, Gary E. Goodman, David S. Alberts, Loretta Marie Itri

Research output: Contribution to journalArticle

55 Scopus citations

Abstract

Retinoids, particularly 13-cis-retinoic acid, have shown great promise against a number of benign, but serious dermatological conditions. In animal models, 13-cis-retinoic acid functions is a potent antipromoter whether a cancer has been initiated by chemical, physical, or viral agents. Additionally, substantial antiproliferative activity of this compound has been demonstrated in vitro in many culture systems. Clinical activity noted against several types of skin malignancies has led to several investigations to determine the anticancer activity of 13-cis-retinoic acid. Response of a variety of preneoplastic and neoplastic lesions of epithelial histology and been demonstrated. The toxicity of 13-cis-retinoic acid largely reflects its tissue distribution with skin and subcutaneous side-effects limiting dose escalation. The pharmacology and pharmacokinetics of 13-cis-retinoic acid has been explored in a number of patients and a long terminal half-life demonstrated. This review will discuss 13-cis-retinoic acid as a good model for a biological response modifier.

Original languageEnglish (US)
Pages (from-to)75-101
Number of pages27
JournalCritical Reviews in Oncology and Hematology
Volume3
Issue number1
DOIs
StatePublished - 1985

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of '13-Cis-retinoic acid: Pharmacology, toxicology, and clinical applications for the prevention and treatment of human cancer'. Together they form a unique fingerprint.

  • Cite this